Multiple Sclerosis, Chronic Progressive
Conditions
Keywords
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Brief summary
Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to Betaferon® treatment.
Interventions
All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Relapsing-remitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients * Having Betaferon treatment, including patients who are * First time using; or * Re-staring; or * Switching from other diseases modifying drugs (DMDs)
Exclusion criteria
* Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence to Betaferon treatment: proportion of patients adhering to Betaferon treatment | at 6, 12, 18 and 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Ways of Coping Questionnaire (WCQ) | at 6, 12, 18 and 24 months |
| Hospital Anxiety and Depression Scale (HAD) | at 6, 12, 18 and 24 months |
Countries
China
Outcome results
None listed